about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Adap­ti­m­mune pledges $312M for Noile-Im­mune's T cell boost­ing tech in dri­ve to de­liv­er on TCR promise

6 years ago
Deals
Cell/Gene Tx

San­ther­a's Duchenne ef­fort gets a boost on pos­i­tive PhI­Ia for al­ter­na­tive steroid va­morolone — though there's a lot ...

6 years ago
R&D

Out to shake up PC­SK9 mar­ket, Med­i­cines Co boasts of piv­otal PhI­II win for in­clisir­an

6 years ago
R&D

Pfiz­er, Astel­las win pri­or­i­ty re­view for Xtan­di sN­DA; Hemi­spherx changes its name

6 years ago
News Briefing

Why would Am­gen want to buy Alex­ion? An­a­lysts call hot­ly ru­mored takeover un­like­ly, but seize the mo­ment

6 years ago
Deals

Build­ing on suc­cess­ful PD-1 pact, Eli Lil­ly li­cens­es di­a­betes drug to Chi­nese part­ners at In­novent

6 years ago
Deals
China

Biotech lead­ers ral­ly be­hind Chi­nese sci­en­tists in US, calls for 'mea­sured' poli­cies in wake of purges

6 years ago
China

Get as much Spra­va­to as you can, Trump or­ders VA while sug­gest­ing J&J should of­fer it to vet­er­ans for free

6 years ago
Pharma

Eight weeks be­tween each HIV treat­ment? GSK notch­es PhI­II win as it chas­es OK for long-act­ing reg­i­men

6 years ago
R&D

SEC calls out lit­tle Ther­a­peu­tic­sMD for its in­sid­er con­tacts with an­a­lysts to boost share price, then halt rout

6 years ago
FDA+

Cowen, Per­cep­tive lead $79.5M Se­ries B for 's­tand­out' biotech shep­herd­ing on­colyt­ic virus to clin­ic

6 years ago
Financing

FDA de­ci­sion on Ver­tex's CF triple will come just ahead of planned CEO shake­up

6 years ago
R&D
FDA+

Fresh from $102M haul, IGM Bio pitch­es $100M IPO as it plots first-in-hu­man tri­al of new an­ti­bod­ies

6 years ago
Financing

Spring­Works seeks $115M to push Pfiz­er drugs across fin­ish line while Sat­suma sells mi­graine play in $86M IPO

6 years ago
Financing

ICER blasts FDA, PTC and Sarep­ta for high prices on DMD drugs Em­flaza, Ex­ondys 51

6 years ago
Pharma

Re­gen­eron puts fin­ish­ing touch­es on $800M ex­pan­sion project close to home

6 years ago
R&D

On the cusp of PhI, An­gel­man-fo­cused biotech scores po­ten­tial buy­out deal from Ul­tragenyx

6 years ago
Deals

Armed with stel­lar — if niche — PhI­II da­ta, Re­gen­eron steers 'break­through' cho­les­terol drug to post-PC­SK9 wa­ters

6 years ago
R&D

Eli Lil­ly's Taltz beats J&J's Trem­fya in pso­ri­a­sis head-to-head — but the mar­ket­ing brawl is just be­gin­ning

6 years ago
R&D
Pharma

Plug­ging in the last piece to its gene ther­a­py puz­zle, AskBio ac­quires Scot­tish syn­thet­ic pro­mot­er com­pa­ny

6 years ago
Deals
Cell/Gene Tx

IBD start­up Lan­dos lands $60M Se­ries B in first test case of Chris Garabe­di­an's lean and mean mod­el at Xon­toge­ny

6 years ago
Financing
Startups

How does TDP-43 bog up the brains of ALS, FTLD pa­tients? AC Im­mune en­lists Penn sci­en­tists to find out

6 years ago
Discovery

Pref­er­en­tial tax poli­cies com­ing for bio­phar­mas set­ting up shop in Shang­hai's newest free trade zone

6 years ago
China

Retrophin paid Mar­tin Shkre­li 'undis­closed sum' to set­tle years­long le­gal dis­putes

6 years ago
People
First page Previous page 92939495969798 Next page Last page
A service from the Financial Times